

## MACRA Funding Opportunity: Measure Development Awardees for the Quality Payment Program

Awardee	Specialty Gap Area	Proposed Measures
The Brigham and Women's Hospital, Inc.	Orthopedic Surgery	<ol style="list-style-type: none"> <li>1. Hospital-level risk-standardized complication rate (RSCR) following elective primary THA and/or TKA (Conversion to e-measure)</li> <li>2. Average pre-and-post-operative change in functional status at one year (other times will be considered) for patients undergoing total hip replacement as measured by one or more of the PROM(s) below:               <ol style="list-style-type: none"> <li>I. PROMIS 10 Global Function</li> <li>II. PROMIS Physical Function 10</li> <li>III. HOOS-PS (Short Form)</li> </ol> </li> <li>3. Patient perceptions regarding care goal achievement following THA and/or TKA and/or Spinal Stenosis surgery</li> <li>4. Opioids NQF 2940, Convert to eMeasure: Use of Opioids at High Dosage in Persons Without Cancer</li> <li>5. Opioids (individual eCQMs) to be developed:</li> </ol>

Awardee	Specialty Gap Area	Proposed Measures
		<p>Hospital-level risk-standardized medication side effect rate following elective THA and/or TKA</p> <ul style="list-style-type: none"> <li>I. Opioid respiratory depression</li> <li>II. Opioid extended use</li> </ul> <p>6. Hospital-level risk-standardized medication side effect rate following elective primary THA and/or TKA</p> <ul style="list-style-type: none"> <li>I. Anticoagulant bleeding</li> </ul>
American Society for Clinical Pathology	Pathology	<ul style="list-style-type: none"> <li>1. Notification to the ordering provider requesting myoglobin or CK-MB (creatinine kinase-muscle/brain) in the diagnosis of suspected acute myocardial infarction (AMI)</li> <li>2. Notification to the ordering provider requesting thyroid screening tests other than only a Thyroid Stimulating Hormone test in the initial screening of a patient with a suspected thyroid disorder</li> <li>3. Notification to the ordering provider requesting amylase testing in the diagnosis of suspected acute pancreatitis</li> <li>4. Rate of critical value reporting for troponin</li> </ul>

Awardee	Specialty Gap Area	Proposed Measures
		<ol style="list-style-type: none"> <li>5. Time interval: critical value reporting for chemistry assess diagnostic accuracy and team-based care</li> <li>6. Rate of communicating results of an amended report with a major discrepancy to the responsible provider</li> <li>7. Rate of notification to clinical providers of a new diagnosis of malignancy</li> </ol>
The Regents of the University of California, San Francisco	Radiology	<ol style="list-style-type: none"> <li>1. Composite radiation dose and quality</li> </ol>
American Psychiatric Association	Mental Health and Substance Use	<p><b>Measurement-Based Care Process Measures:</b></p> <ol style="list-style-type: none"> <li>1. Initial assessment for all patients seen for mental health and substance use care</li> <li>2. Monitoring of symptoms, functioning, and recovery for all patients seen for mental health and substance use care</li> <li>3. Treatment adjustment for all patients seen for mental health and substance use care</li> </ol> <p><b>Measurement-Based Care Outcome Measures:</b></p> <ol style="list-style-type: none"> <li>1. Improvement or maintenance of symptoms for patients with psychosis</li> <li>2. Improvement or maintenance of</li> </ol>

Awardee	Specialty Gap Area	Proposed Measures
		<p>symptoms for patients with suicide risk</p> <ol style="list-style-type: none"> <li>3. Improvement or maintenance of symptoms for patients with opioid misuse</li> <li>4. Improvement or maintenance of functioning for all patients seen for mental health and substance use care s</li> <li>5. Recovery for all patients seen for mental health and substance use care</li> </ol> <p><b>Evidence-Based Treatment Process Measures:</b></p> <ol style="list-style-type: none"> <li>1. Safety plan for individuals with suicide risk</li> <li>2. Initiation of antipsychotic treatment among individuals with first-episode psychosis (FEP)</li> <li>3. Initiation of medication-assisted treatment (MAT) among individuals with opioid use disorder (OUD)</li> </ol> <p><b>Patient Experience of Care Outcome Measures:</b></p> <ol style="list-style-type: none"> <li>1. Patient experience of care for all patients seen with mental health and substance use care</li> </ol>
University of Southern California	Mental Health and Substance Use	<ol style="list-style-type: none"> <li>1. Continuity of Pharmacotherapy for Opioid Use</li> </ol>
Pacific Business Group on Health	Oncology	<ol style="list-style-type: none"> <li>1. Patient Reported Pain in Cancer Following Chemotherapy</li> </ol>

Awardee	Specialty Gap Area	Proposed Measures
		2. Patient Reported Health Related Quality of Life in Cancer Following Chemotherapy.
American Academy of Hospice and Palliative Medicine Inc.	Palliative Care	<ol style="list-style-type: none"> <li>1. Symptom measure - Percent of patients age 18 years and over receiving specialist palliative care who report getting the help they need for their [symptom]; on an item derived from the CAHPS Hospice Survey (whose respondents are bereaved caregivers) and modified for palliative care/seriously ill patient report</li> <li>2. Communication Measure - Percent of patients age 18 years or over receiving specialist palliative care who report feeling heard and understood by their palliative care provider on the Heard &amp; Understood item</li> </ol>